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Abstract 
BACKGROUND:  With skin cancers being among the fastest growing cancers in Sweden, it 
has lead to increased pressure on dermatology clinics everywhere in the country. Standardized 
care processes have improved the situation regarding malignant melanoma and squamous cell 
carcinoma, however general dermatologic issues remain. Several studies have been made on 
teledermatology, many of them with promising results such as shortened time to treat, 
unnecessary visits skipped, planning easier and triaging possible. A logical evolution of 
teledermatology is a mobile form, mobile teledermatology. Studies have been made on this as 
well, however results not as precise as the regular form, although it has been suggested to 
work as a tool for triaging. 
AIM: To investigate whether a direct to consumer mobile teledermatology system can triage 
users correctly to the nearest dermatology clinic for further tests, diagnosing and the right 
treatment and save time. 
METHOD: In 2017, 766 patients used a teledermatology application, out of these 262 were 
recommended to use the application to send a self-referral to nearest dermatology clinic, 105 
users sent a self-referral through this application, these were followed up. For comparison 120 
primary healthcare center referrals and 120 regular self-referrals were obtained. The priorities 
given to each referral were compared, time until first visit in days within each assessment and 
specific diagnoses, and as well time until treatment were compared. 
RESULTS: The difference in distribution of assessments was statistically significant when the 
teledermatology self-referrals were compared with regular self-referrals. The difference 
remained statistically significant when all three groups were compared.  
 3 
There was a statistically significant difference in days waited between all three groups when 
prioritized as 2-4 weeks and 1-3 months, however this only implies that there was a 
significant difference in waiting times between all three groups. Thus teledermatology 
referrals were compared separately to each group, and days waited were only significantly 
lower compared to primary healthcare referrals in 2-4 weeks priority. However there were no 
statistically significant difference in days waited was found in any other priorities or 
diagnoses between the groups. 
CONCLUSION: From data obtained, using a mobile teledermatology application may lower 
the amount of rejected referrals and at the same time find patients with lesions in more need 
of specialist care. Patients with regular self-referrals got an appointment faster than all other 
groups of all priorities analyzed however these type of referrals were rejected the most as 
well. The teledermatology referrals had slightly longer waiting times with a lower percentage 
of rejected referrals, although a significant difference was only found in one priority (2-4 
weeks).   
KEYWORDS: Mobile teledermatology, Referral, Triage 
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Abbreviations 
BCC Basal cell carcinoma 
DCH Diagnostiskt centrum hud 
FTF Face-to-face 
KUH Karolinska university hospital 
MM Malignant melanoma 
NUH Norrland university hospital 
PHC Primary healthcare center 
SAF  Store and forward 
SUH Sahlgrenska university hospital 
TD Teledermatology 
TDA Teledermatology application 
TDR Teledermatology referral 
TDS Teledermoscopy 
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Background 
	
Introduction	
Skin diseases in Sweden and in Western countries in general are a growing concern, 
specifically skin cancers as these have an annual growth of 6% (1).  A reason for this is 
because of our sun-habits and light skin type of the Swedish population, which are two major 
risk factors to develop cutaneous cancer (2). These sun habits include vacations to sunny 
locations, sunbathing in Sweden and use of sun beds (3-5). As these are among the fastest 
growing cancers, which include malignant melanoma and squamous cell carcinoma, 
dermatology clinics all over Sweden have to deal with increased pressure and queue times.  
With the implementation of standardized care processes (Standardiserade vårdföropp, SVF 
(6)) the hope is to decrease waiting times and to treat skin cancers early. However patients 
diagnosed with general skin diseases are left out and sometimes wait longer than three months 
to visit a dermatologist (7, 8). Thus, other solutions for all conditions that can reduce waiting 
times needs to be explored. 
 
The	Current	system	
As of now the way to see a dermatologist in the public healthcare system is through a 
“gatekeeper” system. The primary care physician, at a primary health care centre (PHC), 
makes a judgement if a patient should be referred to a dermatologist. These referrals include 
information in text form and are normally sent by paper through traditional post or fax, these 
do normally not include photographs of the lesion of concern. Another way is through self-
referrals available on web pages of hospitals in Sweden. Though many of these ends up 
rejected (non-prioritized/0-assessed) due to lack of information, and are instead instructed to 
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seek care at a PHC. With the development of todays technology teledermatology (TD) is 
available of use for the general public. These different pathways are displayed in the flow 
chart below (Figure 1.). 
 
 
	
	
	
	
	
	
Teledermatology	
Teledermatology is the practice of dermatology telemedicine, which can be defined as 
exchange of medical information through technologies over a distance on skin concerns. 
Historically records of telemedicine can be tracked 100 years back when Wilhelm Einthoven 
transmitted information of electrocardiograms and encephalograms through an analogue 
telephone network in 1910. In 1920 seafarers had developed a medical advice service based 
on Morse code and voice radio (9).  
Dermatologic information could benefit from such technology, as anamnestic information is a 
major factor to determine diagnosis. Although the dermatology specialty relies heavily on 
visual information as well, meaning pictures would need to be included. Murphy et al. 
Figure 1 Flow chart of the current pathways for a patient to receive an appointment with a 
dermatologist  
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conducted one of the first trials of dermatologic information exchanged through distance in 
1972, which then compared the accuracy between direct examination and examination 
through television with up 89% correct accuracy through the latter mentioned (10). In 1997 
Zelickson and Homan conducted a study in a nursing home including 29 residents with a total 
of 30 dermatologic skin conditions. It was investigated if up to three dermatologists could 
come up with the correct diagnosis and treatment plan of the pictures and information 
provided. With a combination of both picture and history, the physicians were able to 
diagnose 88% of the cases correctly and give the right treatment 90% of the cases (11). In 
2002 Whited et al. investigated if a TD system would benefit waiting times compared to a 
traditional referral system. In this randomized trial it was found that the TD system resulted in 
significantly shorter waiting times with median in days being 42 vs. 127 in the traditional 
group (p<0.001). From the same trial it was found out that unnecessary visits could be 
prevented in the TD group, in the group using the traditional method no unnecessary visits 
could be prevented (p<0.001) (12).  
A systematic review of 78 TD studies by Warshaw et al. was published in 2011 and several 
conclusions were made. Both store and forward (SAF) and live interactive TD were worse 
than Face-to-face (FTF)-visit regarding the diagnostic accuracy, although these methods were 
acceptable (FTF-visits were 5 to 19% better than TD, average absolute difference). In SAF-
TD pictures are taken and sent for evaluation in any given time. With live interaction TD the 
consultation is rather done with the physician in one end and the patient in the other, 
traditionally through a videoconference. However the diagnostic accuracy was significantly 
lower for malignant lesions including squamous cell carcinoma, basal cell carcinoma and 
melanoma. FTF-visits could be avoided potentially with the TD and time to treat in days was 
significantly lower with TD. Patient satisfaction was seen as relatively high. Although not 
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enough information on clinical outcomes using TD were obtained, this is especially important 
for conditions with potential lethal outcomes. (13).  
 
Mobile	teledermatology	
Smart phones have developed rapidly in the last decade, especially built in cameras that are 
capable of taking pictures of very good quality. Mobile telephone networks have developed as 
well and accessibility to Internet is easily attained through 3G or 4G (Third and fourth 
generation of wireless telecommunications technology). Naturally mobile TD developed. In 
one study of mobile TD average diagnostic concordance reached 70% with cellular phones 
(14). This study was made in 2005 on older phones that had worse image quality compared to 
todays standard. Looking at a study made in 2015 by Nami et al. diagnostic concordance 
reached 91.05% and overall therapy 79.80% (15). Börve et al. conducted a study on a 
multimedia message service (MMS)-referral method where dermatologists correctly 
diagnosed 78% of the patients. This study included 40 patients, 32 of which were diagnosed 
with cutaneous tumors (16).  
Dermoscopes are used widely in dermatology and have been proven to be specially important 
in diagnosing malignant pigmented lesions (17). This tool consists of a magnifying plate and 
a polarized light source, which allows the user to see deeper structures of the skin. Such a tool 
can be combined with cellular phones for improved pictures, and when such pictures are 
included in the consultation it is known as mobile teledermoscopy (TDS). When these types 
of pictures are included in the consultation Ferrandiz et al. reached sensitivity of 92.86% and 
specificity of 96.24%. With regular TD sensitivity reached 86,57% and specificity 72.33% 
(18). Using TDS May et al. concluded that such a method could work as a tool for prioritizing 
patients to reduce waiting times, as did Borve et al. (19, 20). 
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Healthcare	costs	
There are some studies made on economic viability of a TD system, as Pak et al. concluded 
that SAF-TD was a cost saving strategy compared to a traditional consultation method (21). 
Eminovic et al. found out that cost savings could be made if users of a TD-system were living 
further than 75 km from the selected clinic (22). This is especially important in Sweden, as 
many people do not have access to specialist health care as easily depending on the region.  
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Material and methods 
Teledermatology	platform	group	
During 2017 from the 1 January until the 1 October, 766 people have used First Derm (iDoc 
24 ®), a mobile teledermatology platform available to download (Apple store, Google store 
or used through their Internet webpage). The main goal of this service is to provide the user 
with a preliminary diagnosis and further instructions based on this. Unnecessary visits to 
dermatologists and PHC’s can be prevented doing this. 
How the teledermatology application (TDA) essentially works is the user taking two pictures 
of the lesion and providing a description of the lesion. The pictures were taken in two ways, 
one close to the lesion, 10 cm away, and one picture further away approximately 20 cm. If the 
user had access to an external dermoscope this could be attached on the phone for a TDS 
picture. The description included type of lesion (Nevus or other types), duration, and an 
opportunity for the user to describe the lesion with their own words. Personal information 
(age, sex, city and country) was requested as well.  
A dermatologist assessed the information provided with the user remaining anonymous. 
Within 24 hours the user was answered and provided with an eight-digit code to view this 
case online. Prices start from 319 SEK for an answer within 24 hours. The user had an option 
to pay more for a faster answer (499 SEK, 8 hours). 
This response could be a preliminary diagnosis of a potentially malignant lesion where the 
user was provided with further instructions and a recommendation to send a self-referral 
through the TDA. Another response of a less threatening issue the user was provided with 
exact instructions, for example to obtain a class I topical steroid to be applied to the concern 
with specific instructions of the frequency and application.  
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Out of the 766 users, 158 were recommended to self-treat; instructions were included. Several 
users (49) were in need of medical assessment, however not specifically by dermatologists. 
Out of these 44 were recommended to see a primary care physician, five were recommended 
to see a physician specialized in sexually transmitted infections (STI-physician). Users with 
benign lesions (297) were informed about the condition and such lesions did not require 
medical attention. However these users were instructed to check these lesions for any sort of 
change (growth, color change, bleeding etc.). Lesions considered benign included seborrheic 
keratosis, benign nevi for example.  
The remaining users (262) were recommended to see a dermatologist and to send a tele-
dermatology-referral (TDR) through the TDA (37 Swedish clinics in total have received these 
type of referrals). Only 105 users sent a TDR, these were included in the study. No 
information could be obtained on the other users. The TDA was used of their initiative. In 
table 1 all the users have been summarized with specific recommendations. 
 
Table 1 Specific recommendations provided to users by dermatologists of the TDA in amount. 
All specified into date of usage of the TDA and the total period. 
 
 Date 
(day/month) Dermatologist 
Primary 
care 
physician 
STI-
physician 
Self-
treatment 
Benign 
lesions 
Total (within 
period) 
1/1 - 1/3 38 10 0 24 36 108 
1/3 - 1/5 40 4 2 31 41 118 
1/5 - 1/7 95 12 0 48 121 276 
1/7 - 1/9 72 15 2 37 84 210 
1/9 - 1/10 17 3 1 18 15 54 
1/1 – 1/10 
(all) 262 44 5 158 297 766 
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Groups	for	comparison	
For comparison 120 PHC-referrals and 120 regular self-referrals received at Sahlgrenska 
University Hospital (SUH) were obtained. There were no inclusion criteria for the different 
type of referrals. The PHC-referrals were obtained based on the visit to SUH, with the first 
visit 2 January 2017, until an amount of 120 was reached. The regular self-referrals were 
obtained based on the date of assessment until an amount of 120 was reached. 
 
Table 2 Diagnosis distribution. Diagnoses only found in the self-referrals group are lesions 
described by patients. 
Diagnosis  PHC-referral Self-referral TDR 
Total 120 120 105 
Skin change 21 38 0 
Atypical nevus 0 0 29 
Rash 4 18 0 
Basal cell carcinoma 11 3 25 
Suspicious nevus 9 9 0 
Malignant melanoma 8 0 14 
Psoriasis 8 7 0 
Squamous cell carcinoma 8 1 0 
Actinic keratosis 6 1 8 
Acne 5 4 1 
Eczema 5 5 0 
Cutaneous horn 5 2 0 
Suspicious wound 3 5 0 
Atopic eczema 2 0 1 
Pyogenic granuloma 2 0 1 
Suspicion of malignancy  2 0 0 
Seborrheic keratosis 1 0 5 
Condyloma acuminatum 0 1 3 
Seborrheic dermatitis 0 1 3 
Dermatitis 1 0 3 
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Intradermal nevus 1 0 2 
Lentigo 1 0 1 
Abscess 1 0 0 
Alopecia 1 0 0 
Alopecia areata 1 0 0 
Birt-Hogg-Dubés syndrome - 
Laser treatment 1 0 0 
Chronic urticaria 1 0 0 
Extended excision of SCC 1 0 0 
Verruca plantaris 1 0 0 
Full body examination, post-
surgery malignant melanoma 1 0 0 
Lichen planus 1 0 0 
Lichen sclerosus et atrophicus 1 0 0 
Heredity of malignant lesions 1 0 0 
Mastocytosis 1 0 0 
Nevus sebaceus 1 0 0 
Onychomycosis 1 0 0 
Osteogenesis imperfecta 1 0 0 
Rosacea 1 3 0 
Vitiligo 1 0 0 
Dermatofibroma 0 0 1 
Folliculitis 0 0 1 
Giant cell tumour 0 0 1 
Insect bite 0 0 1 
MB Paget 0 0 1 
Necrobiosis lipodica 0 0 1 
Perioral dermatitis 0 1 1 
Phototoxic reaction 0 0 1 
Tinea corporis 0 0 1 
Atypical hairiness 0 1 0 
Bald spots 0 1 0 
Cartilage formations  0 1 0 
Dryness  0 1 0 
Fungal infection 0 1 0 
Genital infection 0 1 0 
Hair loss 0 1 0 
Hyperhidrosis 0 2 0 
Pigmented nevus 0 1 0 
Pigmented spots 0 2 0 
Palmoplantar pustolosis (PPP) 0 2 0 
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Scabies 0 2 0 
Scalp lesion 0 1 0 
Scar 0 1 0 
Skin change ("bubbles" 
described by patient) 0 1 0 
Wart 0 2 0 
 
 
 
Table 3 Age distribution 
  
Median 
(years) 
Mean 
(years) Max (years) Min (years) 
TDR 44,5 46,3 73 13 
PHC-referral 51,9 53 94 1 
Self-referral 46,5 46 87 8 
 
Table 4 Gender distribution. In the TDR-group one user failed to mention gender 
  Male Female Missing 
TDR 52 52 1 
PHC-referral 70 50 0 
Self-referral 66 54 0 
 
	
Followed	up	data	
Further data was collected on the patients who had visited the clinic. This data included final 
diagnosis, date of visit, performed procedure (Biopsy, dermoscopy, excision) and date of 
procedure. The histopathological report was also collected. Waiting times in the whole 
country depended on a system of priority, which was based on the severity of the problem. In 
SUH this system was based on weeks with the highest priority being 0-1 week; these patients 
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were scheduled for an appointment within seven days. The lowest priority for an appointment 
was 1-3 month’s assessment; actinic keratosis was issued with this assessment for example. 
Rejected referrals (non-prioritized/0-assessment) did not receive an appointment, but were 
instead instructed to seek care first-hand at a PHC. 
 
Statistical	analyses		
The distribution of assessments/priorities was analyzed with Fischer’s exact test because of 
the small sample followed up in the TDR-group. The TDR-group was compared with the 
regular self-referral group, as these referrals were the only ones rejected. All three groups  
(TDR, PHC-referrals and regular self-referrals) were compared with the rejected referrals 
excluded from the analysis. 
Days waited were analyzed with Kruskal-Wallis test with all three groups included as the 
days were not distributed evenly. The groups were separated into sub groups based on 
assessment and diagnosis, to see if there was any difference. The TDR-group was compared 
separately to the other two groups with Mann-Whitney U test to determine if the difference in 
waiting time would remain statistically significant. This test was used, as data was not evenly 
distributed. 
In previous studies times to treat in days could be shortened because of included pictures in 
the TD consultation method enabling a plan to treat already at received referral (12, 19). 
Lesions in need of excision were treated surgically on the first visit in all groups; there were 
only three cases in total (one in the TDR- group, two in the PHC-group) that received 
treatment after the first visit. Because of this no further analysis was made. 
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Ethical	considerations	
No ethical permit was obtained as this report would not be published and is considered a 
student degree project thus covered by the law (SFS 2003:460 2§) (23). Based on this all 
hospitals were initially contacted formally, requesting journals connected to the TDR. 
However all clinics required patient consent. All included users were contacted formally, 
requesting consent to take part of journals connected to the TDR. 
From the initial contact with hospitals, Karolinska University hospital (KUH) and Norrlands 
University hospital (NUH) had informed that self-referrals were not accepted. Patients that 
sent TDR’s to KUH were instead instructed to seek care at private dermatology clinics in 
Stockholm. An agreement had been made between these clinics and the Swedish healthcare 
system to take care of such referrals. These patients were contacted and asked where they had 
received care instead. NUH instructed such patients to seek care at PHC’s first-hand; these 
users were contacted similarly to those of KUH. 
SUH had the highest amount of TDR’s, with 30 users in total. To access these journals a 
specific permit was obtained and approved by the head of dermatology (verksamhetschef). 
The same permit was obtained to gain access to the 120 PHC- and 120 regular self-referrals. 
Nine of the TDR’s were rejected and were contacted as those of KUH and NUH.  
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Results 
Exclusions	
In the TDR-group 54 referrals were excluded, as these could not be followed up. Out of these 
one user declined consent, one clinic reported no information of such a referral, 47 failed to 
give consent in time. The patient that had sent the referral to the clinic without any 
information could not be contacted. Of the remaining five from the excluded referrals, two 
users provided the wrong address thus no contact could be made. Consent was obtained from 
three more users, however the clinic failed to send any journals. This clinic was contacted 
several times but informed that no requests had been received. 
KUH and NUH informed that self-referrals were not accepted, thus six more TDR’s 
considered rejected were included. 
 
Table 5 Followed up TDR’s with amount of visits, distribution of malignant and benign 
lesions. Actinic keratosis, BCC, malignant melanoma was considered malignant lesions. 
Amount of days waited in mean value, ‘N’ meant no visit of any patients. Numbers within 
brackets are amount of visits of the specific type of lesion. 
Hospital Amount Visits Malignant Benign 
Mean wait 
time (days) 
Sörmland hospital 1 0 0 1 N 
KUH 4 0 0 4 N 
NUH 2 0 1 1 N 
HudDoktorn, Örebro 1 1 1 0 77 
DCH, Stockholm 1 1 0 1 63 
Ryhov County hospital 2 2 1 1 60,5 
Uddevalla hospital 5 4 4 (3) 1 59 
SUH 29 14 15 (7) 14 (7) 58,6 
DCH, Malmö 3 3 1 2 45 
Visby hospital 1 1 0 1 33 
Södersjukhuset 1 1 0 1 28 
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Södra Älvsborgs sjukhus 1 1 1 0 25 
Kungsholmens dermatology 
clinic 2 2 0 2 21 
Kalmar hospital 1 1 1 0 16 
Växsjö hospital 1 1 1 0 15 
Falun hospital 1 1 0 1 13 
 
 
Table 6 Rejected TDR’s with diagnosis and which hospital rejected the referral. 
Hospital Diagnosis 
SUH Atypical nevus 
SUH Atypical nevus 
SUH Basal cell carcinoma 
SUH Basal cell carcinoma 
SUH Condyloma acuminatum 
SUH Condyloma acuminatum 
SUH Seborrheic keratosis 
SUH Tinea corporis 
Mälarsjukhuset Necrobiosis lipoidica 
KUH Pyogenic granuloma 
KUH Perioral dermatitis 
KUH Seborrheic keratosis 
KUH Atypical nevus 
NUH Basal cell carcinoma 
NUH Mb Paget 
 
 
No referrals from the other two groups were excluded as information such as assessment 
could be obtained. The TDR-group diagnoses with excluded referrals and referrals with 
assessments are displayed below (table 9). As no referrals were excluded from the other 
groups they remained unchanged. 
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Table 7 Age distribution after exclusions, and TDR’s with assessments 
  
Median 
(years) 
Mean 
(years) Max (years) Min (years) 
TDR (Excluded) 44,5 46,4 72 13 
TDR (Assessments) 45 47 72 13 
PHC 51,9 53 94 1 
Self-referral 46,5 46 87 8 
 
 
Table 8 Gender distribution after exclusions, and TDR’s with assessments 
  Male Female Total 
TDR (Excluded) 30 29 59 
TDR (Assessments) 18 12 30 
PHC 70 50 120 
Self-referral 66 54 120 
 
 
Table 9 Diagnosis distribution. TDR (included) are followed up referrals, TDR (assessment) 
are those from SUH. Diagnoses only found in the self-referrals group are lesions described 
by patients. 
Diagnosis PHC-referrals 
Self-
referrals 
TDR 
(included) 
TDR 
(assessments) 
Total 120 120 59 30 
Skin change 21 38 0 0 
Basal cell carcinoma 11 3 16 9 
Atypical nevus 0 0 18 10 
Suspicious nevus 9 9 0 0 
Malignant melanoma 8 0 8 6 
Condyloma acuminatum 0 1 2 2 
Psoriasis 8 7 0 0 
Squamous cell carcinoma 8 1 0 0 
Actinic keratosis 6 1 3 0 
Acne 5 4 0 0 
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Eczema 5 5 0 0 
Cutaneous horn 5 2 0 0 
Rash 4 18 0 0 
Suspicious wound 3 5 0 0 
Pyogenic granuloma 2 0 1 0 
Atopic eczema 2 0 0 0 
Suspision of malignancy 2 0 0 0 
Seborrheic keratosis 1 0 2 1 
Dermatitis 1 0 1 0 
Intradermal nevus 1 0 1 0 
Lentigo 1 0 1 1 
Abscess 1 0 0 0 
Alopecia 1 0 0 0 
Alopecia areata 1 0 0 0 
Birt-Hogg-Dubés 
syndrome - Laser 
treatment 
1 0 0 0 
Chronic urticaria 1 0 0 0 
Extended excision of SCC 1 0 0 0 
Verruca plantaris 1 0 0 0 
Full body examination, 
post-surgery Malignant 
melanoma 
1 0 0 0 
Lichen planus 1 0 0 0 
Lichen sclerosus et 
atrophicus 1 0 0 0 
Heredity of malignant 
lesions 1 0 0 0 
Mastocytosis 1 0 0 0 
Naevus sebaceus 1 0 0 0 
Onychomycosis 1 0 0 0 
Osteogenesis imperfecta 1 0 0 0 
Rosacea 1 3 0 0 
Vitiligo 1 0 0 0 
Giant cell tumour 0 0 1 0 
MB Paget 0 0 1 0 
Necrobiosis lipodica 0 0 1 0 
Perioral dermatitis 0 1 1 0 
Seborrheic dermatitis 0 1 1 0 
Tinea corporis 0 0 1 1 
Atypical hairiness 0 1 0 0 
Bald spots 0 1 0 0 
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Cartilage formations 0 1 0 0 
Dryness 0 1 0 0 
Fungus infection 0 1 0 0 
Genital infection 0 1 0 0 
Hair loss 0 1 0 0 
Hyperhidrosis 0 2 0 0 
Pigmented nevus 0 1 0 0 
Pigmented spots 0 2 0 0 
Palmoplantar pustolosis 
(PPP) 0 2 0 0 
Scabies 0 2 0 0 
Scalp lesion 0 1 0 0 
Scar 0 1 0 0 
Skin change ("bubbles" 
described by patiet) 0 1 0 0 
Wart 0 2 0 0 
 
 
Assessment	
A difference in distribution of priorities was observed between all groups compared. With all 
priorities, the PHC-referrals were excluded from the first analysis as these could not be 
rejected or non-prioritized, thus only TDR’s and regular self-referrals were included for this 
part. The difference in distribution of assessments was statistically significant (p=0.000013, 
Fischer’s exact test), however there were priorities in these groups that could only be found in 
one another. These included one 0-1 prioritized referral in the TDR-group, one 0-2 prioritized 
in the self-referral group and two of which were not prioritized at all in the self-referral group. 
With these referrals excluded the difference remained statistically significant (p=0.000009, 
Fischer’s exact test. Figure 2, table 10). 
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Table 10 Assessments of referrals specified in amounts and percentage of each 
group, 0-1 week-, 0-2 weeks-assessed referrals have been excluded and referrals 
without any assessments as well. 
 
 
Total Self-referral TDR 
Assessment Rejected referral Count 70 9 79 
% within Type 59,8% 31,0% 54,1% 
2-4 weeks assessment Count 5 11 16 
% within Type 4,3% 37,9% 11,0% 
1-3 months assessment Count 42 9 51 
% within Type 35,9% 31,0% 34,9% 
Total Count 117 29 146 
% within Type 100,0% 100,0% 100,0% 
Figure 2 Distribution of assessments of the referrals, comparing regular self-referrals 
and TDR’s in percentage. 0-assessment is the same as rejected. 0-1 week-, 0-2 weeks 
assessed referrals are excluded and referrals with missing information are excluded. 
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For the second analysis the PHC-referrals were included as well and referrals that were 
rejected were excluded completely. Similarly to the previous analysis the difference was 
statistically significant (p=0.002, Fischer’s exact test) and as in previous analysis there were 
referrals with priorities that could on be found in one group. These referrals were those 
mentioned previously and three additional 0-1 week prioritized referrals, two 0-2 weeks 
referrals and one more referral missing information. These were excluded. Although the 
difference remained statistically significant in this analysis (p=0.000335, Fischer’s exact test. 
Figure 3, table 11). 
 
 
 
 
 
Figure 3 Distribution of assessments in percentage. Comparing all types of 
referrals. Rejected referrals are excluded from this pie chart. Referrals assessed as 
0-1 week, 0-2 weeks have been excluded, and referrals missing information have 
been excluded as well. 
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Waiting	times	
An analysis to compare the waiting times between all types of referrals depending on the 
priority set. The priorities that were analyzed were 1-3 months-, 2-4 weeks- and 0-1 weeks 
prioritized referrals as at least on such referral could be found in two or more groups. In the 
referrals prioritized 1-3 months and 2-4 weeks the difference was statistically significant 
between all three groups, however this does not imply lower waiting times in any type of 
referral. Thus an analysis comparing the TDR’s separately to the other types of referral was 
made. A Mann-Whitney U test indicated that days waited for referrals prioritized as 2-4 
weeks were significantly lower for TDR’s compared to PHC-referrals (p=0.001, Mann-
Whitney U test, Fig 4, table 12). 
 
 
Table 11 Assessments of referrals specified in amounts and percentage of each group. 
Rejected referrals are excluded from this table. 0-1 week-, 0-2 weeks-assessed referrals 
have been excluded and referrals without any assessment as well. 
 
 
Total Self-referral TDR PHC-referral 
Assessment 2-4 weeks 
assessment 
Count 5 11 25 41 
% within Type 10,6% 55,0% 34,7% 29,5% 
1-3 months 
assessment 
Count 42 9 47 98 
% within Type 89,4% 45,0% 65,3% 70,5% 
Total Count 47 20 72 139 
% within Type 100,0% 100,0% 100,0% 100,0% 
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Table 12 Amount of days waited, in all groups of referrals assessed 2-4 weeks. 
 Median (days) Mean (days) 
TDR 31 31.4 
PHC 44 53.6 
Self-referral 26 25.8 
 
 
 
Figure 4 Boxplot comparing the waiting times in days in all three groups assessed as 2-4 weeks priority with 
outliers excluded. Thicker black lines towards the centre are the median values (table 12.) FD = TDR, ER = Self-
referrals and VC=PHC-referrals. 
 
Although none of the other variations (2-4 weeks, 1-3 months) were statistically significant. 
Referrals prioritized as 0-1 weeks were only found in the TDR-group and the PHC-group and 
the difference in days waited were not statistically significant (p=0.546, Kruskal-Wallis test).  
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The same analyses were made based on the preliminary diagnosis on the waiting times with 
malignant melanoma, basal cell carcinoma, and actinic keratosis included. Although waiting 
times were lower for TDR’s and regular self-referrals, none of these results were statistically 
significant as the sample size was small, thus no further analyses were made on this data. 
 
 
Time	to	treat,	waiting	time	–	Diagnosis	specific	
Malignant melanoma – First-time visit 
Only referrals from the TDR- and PHC-group were diagnosed with malignant melanoma.  
The difference in days waited of referrals diagnosed as malignant melanoma was not 
statistically significant between TDR and PHC-referrals (p=0.236, Kruskal-Wallis test). 
In total there were 19 with this diagnosis who had visited a dermatologist, seven from the 
TDR group and 12 from the PHC-group. The median value in days in the TDR-group was 20 
days and 39.5 days for the PHC-group. The mean values were 18.7 days for the TDR-group 
and 33.2 days for PHC-group. 
Of the users with malignant melanoma in the TDR-group, five sent referrals to SUH where 
the mean waiting time in days was 24.4. The remaining two visited the county hospital in 
Kalmar with a waiting time of 16 days, and the Central hospital in Växsjö with a waiting time 
of 15 days. 
In the TDR-group two of the users required surgical intervention as the other five were 
assessed as benign lesions. Both users had the lesion surgically excised, with one patient 
treated the first day of visit and the other one eight days after. Both lesions were 
histopathologically confirmed as malignant melanoma (MM) in situ. There was a TDR 
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prioritized as 2-4 weeks, however this period had been exceeded and no information was 
available if the patient had cancelled or rescheduled the appointment.  
In the PHC-group four patients received treatment as the remaining eight were assessed as 
benign lesions. These patients were treated surgically, with two patients treated on the first 
day of visit, one the day after, and the remaining patient treated nine days after the first visit. 
Of all these lesions only one was confirmed histopathologically as MM in situ. The remaining 
lesions were reported as benign nevi and BCC. 
 
Atypical nevus 
There were 13 users in total followed up diagnosed with atypical nevus, no referrals with this 
diagnosis was found in the other groups. Out of these seven had visited SUH, with a mean 
waiting time of 44.6 days. The remaining users had visited different hospitals (Table 16). 
SUH rejected two referrals diagnosed with atypical nevus, and one referral was assessed, as 1-
3 month’s priority however this patient had not yet visited the clinic.  
 
Table 13 Amount of days waited of referrals diagnosed with atypical nevus for specific 
hospitals.  
Waiting time (days) Hospital 
63 Diagnostiskt Centrum Hud, Stockholm 
37 Ryhov County hospital 
33 Visby hospital 
28 Södersjukhuset 
25 Uddevalla hospital 
13 Falun hospital 
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Discussion 
Design	of	study	
The amount of followed up TDR’s were low compared to those of the other groups, especially 
assessed referrals as these were limited to SUH. The time factor was one of the reasons for 
this as 47 patients failed to send consent in time. Journals were not sent in time from one 
clinic as well 
In a future study of similar design followed up referrals could potentially be limited to one 
hospital or a single region in Sweden. There are different systems in the country regarding the 
type of referrals accepted. The TDR’s followed up in this study were considered the same as 
regular self-referrals even though all of these had been assessed by a dermatologist. This was 
an issue in larger hospitals such as NUH and KUH as self-referrals were not accepted in 
general. Although in Stockholm an agreement between private dermatology clinics and the 
Swedish healthcare system had been reached. This meant that referrals of this type were 
accepted with no additional cost for the patient as it was funded by the Swedish healthcare 
system. 
The difference in time was another issue of this study. The TDR’s were all from 2017, 
however referrals from the other groups were primarily from 2016. In this period the majority 
of the patients waited longer than three months, this number has improved in 2017. This is 
described in detail in the next headline. 
All groups were different regarding diagnoses and age distribution. Patients without general 
knowledge of dermatologic conditions wrote regular self-referrals. Lesions were described 
based on looks, for example as a “skin change that is red” but never as atypical nevus unless 
 30 
the patient had experienced a similar lesion before. The TDR’s and PHC-referrals were 
diagnosed similarly though. In both the PHC-group and regular self-referral group the patients 
were generally older. Older patients could potentially benefit using a TD-system as amount of 
visits could be decreased and even avoided. Generally all groups had a higher amount of male 
patients. 
 
Waiting	times	and	treatment	
Users of TDR’s and regular self-referrals had the shortest waiting times of all assessments 
compared, previous studies reported similar results however these were analysed differently 
(12, 19). Although days waited were only significantly lower for the TDR-group compared to 
the PHC-group in referrals prioritized as 2-4 weeks.  
However the majority of referrals from the PHC-group were from 2016, which was before 
SUH had implemented healthcare guarantee (Vårdgaranti) (24). This meant guaranteed visits 
to dermatologists within three months. This could also explain the difference in days waited 
even though the referrals had been prioritized similarly.  
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Figure 5 (a, b) Percentage of patients visiting a dermatologist within three months in whole of Sweden and the 
western region compared, January 2016 – November 2017. The blue line represents the whole country. The 
black line represents the western region of Sweden. Source: http://www.vantetider.se/Kontaktkort/Vastra-
Gotalands/SpecialiseradBesok [Last accessed 2 February 2018] 
 
The shortest waiting times were observed in the regular self-referral group, although the 
majority of these referrals were also rejected. Only two patients with malignant lesions 
(actinic keratosis, BCC) received an appointment using regular self-referrals because of 
previous history of similar lesions. An explanation for the lower waiting times could be that 
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referrals accepted in this group were considered especially in need of treatment, as a sufficient 
description was provided by the patient. 
In the self-referral group it was observed that eight rejected referrals had received an 
appointment, although this was with PHC-referrals. All rejected referrals were instructed to 
seek care at a PHC as previously mentioned. Patients of rejected referrals were contacted with 
traditional post, phone call or a referral response. 
Generally all patients in the all groups received treatment on the first visit. However there 
were exceptions in the TDR-group and PHC-group. All these patients were diagnosed with 
malignant melanoma and were treated surgically with no complications. 
 
Costs	
No analysis was made regarding cost savings in this study. Many users of the TDA were from 
smaller regions of Sweden, and as stated by Eminovic et al. patients living further than 75 km 
from selected clinic could benefit the Swedish healthcare system economically (22). Although 
no analysis of this was made but should be looked into as previous results suggests economic 
savings. 
 
Risks	
As stated by Warshaw et al. diagnostic accuracy was significantly lower using TD for 
malignant lesions (13). Only users that sent self-referrals through the TDA were followed up, 
furthermore exclusions were made. None of the excluded users were followed up and neither 
any of the other recommendations. A potential risk is missing a potential malignant lesion 
with lethal outcomes. However no analysis of this had been made.  
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Regional	differences	-	TDR	
Hospitals such as KUH and NUH did not accept the TDR’s as these were considered the same 
as regular self-referrals. As mentioned previously an agreement had been made with private 
dermatology clinics in Stockholm to take care of self-referrals. NUH instructed everyone with 
self-referrals to seek care at PHC’s first-hand. Of these rejected referrals there was only one 
malignant lesion (BCC). This user was contacted but did not follow the instructions provided 
by the hospital (NUH).  
Referrals issued as malignant melanoma had lower waiting times in smaller hospitals 
compared to SUH. For the smaller hospitals it took 15 and 16 days respectively, while the 
mean waiting time in days was 24.4 for SUH. 
Referrals issued as atypical nevus were accepted in all clinics except SUH where two out of 
ten were rejected. The remaining referrals were assessed differently. Waiting times of this 
diagnosis varied between all clinics.  
 
SUH potentially have seven more visits as six of these referrals were prioritized as 1-3 months 
and one as 2-4 weeks, the remaining referrals were rejected. The referral prioritized as 2-4 
weeks was issued as malignant melanoma and had exceeded the waiting time. No information 
could be obtained of the current status. Of the referrals prioritized 1-3 months, four of these 
were issued as BCC, one as atypical nevus, and the remaining one as atopic eczema. The 
rejected referrals with specific diagnoses are listed in table 6. 
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In Uddevalla hospital no information at all could be found on one patient. Johannesberg PHC 
in Härnösand informed that no TDR had been received. In Östergötland one patient had 
cancelled the appointment, because the lesions had resolved. 
Generally referrals issued with malignant diagnoses received an appointment in all clinics 
except NUH, however several benign lesions in need of assessment by a dermatologist were 
rejected. Clinics such as KUH and NUH did not accept self-referrals. A possible explanation 
of this may be that these clinics were overwhelmed by PHC-referrals and accepting several 
types would be impossible. 
The waiting times varied between smaller and larger clinics. For example in Stockholm, 
Kungsholmens dermatology clinic had a mean waiting time of 21 days while it was 63 days in 
DCH, Stockholm. Smaller clinics such as HudDoktorn in Örebro had a waiting time of 77 
days while it was only 13 days in Falun hospital. However all these were diagnosed 
differently thus it is hard to draw any conclusions.   
 
The	future	of	commercial	TD	
A large majority of patients that used regular self-referral and PHC-referrals could use the 
TDA for a first time visit to a dermatologist. Those in the regular self-referral group could 
benefit from the TDA as many of these patients were concerned about skin changes or 
suspicious nevi. All of these referrals of these concerns were rejected in this group, although 
in the TDR-group the majority of referrals issued as suspicious pigmented lesions were 
followed up. In the PHC-group there were referrals issued with post-surgery full body 
examination, these could potentially benefit from using a TDA, however this would require 
the user to provide sufficient information. Although there would be a notable variation in 
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description evidently seen in the regular self-referrals and also the TDA descriptions, with 
some users providing detailed descriptions and some rather lacking information.  
TD has risks as well, as concluded by Warshaw et al. malignant lesions were significantly 
lower regarding diagnostic accuracy (13). There were also users that provided descriptions 
lacking information. Pictures provided by the users varied in quality, although if the quality 
was not sufficient the user was instructed to send new pictures with no extra costs. These 
potentially affect the outcome negatively, such as providing the user with the wrong 
preliminary diagnosis thus missing a potential malignant lesion. 
For continuous usage of a commercial TDA the risks have to be considered. Although in the 
TDR-group several patients received appointments directly, thus unnecessary visits could be 
skipped. Several of the users of the TDA were also instructed to self-treat or simple wait and 
observe. These actions are both economically viable and also relieve pressure on the Swedish 
healthcare system, however no analysis of this has been made.  
Mobile TD has been recently introduced into a commercial form, which is why results in this 
study are varied. For the upcoming years mobile TD may develop similarly to TD and regular 
mobile TD, as smart phones are constantly developing and the general public learning about 
dermatologic lesions. TDA’s such as the one analysed in this study may develop regarding the 
accessibility for the users as the applications itself is developing. However these are only 
speculations based on previous studies and results collected in this study. 
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Conclusion 
Based on results from this study it is hard to draw any conclusions, as the sample analysed 
was small. A statistical significant in distribution of assessments was seen between all groups. 
The TDR-group had higher amount high-prioritized referrals in percentage than the other 
groups. The percentage of rejected referrals was also lower than regular self-referrals. 
Generally the waiting times were shorter for both TDR’s and self-referrals than PHC-
referrals. Regular self-referrals had the shortest waiting times based on assessment, however 
these were rejected the most as well. TDR’s had slightly longer waiting times than regular 
self-referral with less rejected referrals in percentage. Although waiting times were only 
significantly lower between TDR-group and PHC-group in referrals prioritized as 2-4 weeks.  
For future studies we recommend further collection of data regarding TDR’s. 
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Populärvetenskaplig sammanfattning 
Hudcancer är bland de snabbast ökande cancertyperna i Sverige sett ur Socialstyrelsens data 
på cancerincidens, med hela 6% årlig ökning. Detta har medfört ökat tryck på hudkliniker runt 
om i landet. Med standardiserade vårdförlopp (SVF) har man kunnat förbättra situationen för 
malignt melanom samt skivepitelcancer, dock har generella dermatologiska åkommor långa 
väntetider fortfarande. Flera studier har de senaste årtionden gjorts på teledermatologi vilket 
har visat goda resultat för väntetider, behandling, samt onödiga besök som kunnat hindras och 
dessutom möjliggjort planering för patienter innan de ens besökt kliniken. Med utveckling av 
dagens teknologi har även en mobil form utvecklats, mobil teledermatologi som även visat 
goda resultat dock inte lika bra som den vanliga formen. 
I denna studie har man följt upp 105 användare av en mobil teledermatologi tjänst som har 
blivit rekommenderade att söka specialistvård. Utifrån detta har de skickat en remiss till vald 
hudklinik. Målet är att undersöka om en sådan tjänst kan triagera patienterna rätt och även 
leda till snabbare besökstid hos en specialist. Man har även tagit fram 120 remisser skickade 
från vårdcentral, samt 120 egenremisser skickade av patienter till Sahlgrenska 
Universitetssjukhuset för att jämföra hur dessa har bedömts och hur lång tid dessa patienter 
har fått vänta. 
Med samlad data var skillnaden signifikant gällande bedömningarna mellan de olika 
remisserna. Det var även signifikant skillnad i distribution av väntetiderna mellan de olika 
grupperna i 2-4 veckors bedömda remisser, samt 1-3 månaders bedömda remisser. Detta 
innebär dock enbart att det finns skillnad i väntetid mellan de tre gruppern. därför jämfördes 
teledermatologi-remisserna separat med de andra grupperna. Väntetiden var signifikant lägre 
jämfört med vårdcentralsremisser enbart för remisser med 2-4 veckors prioritet. 
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Samlad data antyder att andelen nekade remisser kan sänkas med mobil teledermatologi och 
samtidigt skicka in patienter i större behov av specialistvård baserat på andelen 2-4 veckors 
bedömda remisser. Patienter med egenremisser fick vård snabbast, dock var dessa mest 
benägna att få sin remiss nekad vilket teledermatologi-remissen hade lägre andel av. Patienter 
som använt sig av teledermatologi-tjänsten hade kortare väntetid än vårdcentralsremisserna. 
Vårdcentralsremisserna var dock från 2016, dessa hade i regel väldigt långa väntetider, men 
med införande av ett mål under 2017 på Sahlgrenska Universitetssjukhuset följer man i regel 
upp alla patienter inom bedömningen man fått. Under 2016 träffade färre än hälften av 
patienter en specialist inom 3 månader, detta nummer ligger på 79% November 2017. Dock är 
det svårt att dra en slutsats utifrån detta eftersom mängden egenremisser baserade på 
teledermatologi-tjänsten var begränsad. Vi rekommenderar ytterligare insamling av data för 
framtida studier. 
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